| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
HDAC11 (IC50 = 3 nM)
FT895 targets histone deacetylase 11 (HDAC11), a unique member of the HDAC family with both histone and non-histone deacetylase activity. HDAC11 is expressed in specific tissues and certain cancer cell lines. As a highly selective HDAC11 inhibitor with an IC₅0 of 3 nM, FT895 enables precise interrogation of HDAC11-dependent biology. Its selectivity over other HDAC family members is >1000-fold. |
|---|---|
| ln Vitro |
FT895, an extremely selective HDAC11, demonstrates over 1000-fold selectivity against ten more HDAC family members [1].
In vitro, FT895 is a potent and specific HDAC11 inhibitor with an IC₅0 of 3 nM. It exhibits over 1000-fold selectivity against the other 10 members of the HDAC family. FT895 has antifungal and antitumor activity, inhibiting HDAC11 expression and limiting EV71 replication in vitro. Its high selectivity makes it a valuable tool for studying HDAC11 biology. |
| ln Vivo |
In vivo studies of FT895 are focused on evaluating its efficacy in animal models of cancer, fungal infections, and viral infections. As a highly selective HDAC11 inhibitor, the compound may have therapeutic potential in these areas. Further in vivo studies are needed to fully characterize its efficacy, safety, and pharmacokinetic profile.
|
| Enzyme Assay |
For in vitro enzyme assays, FT895 is evaluated using HDAC activity assays that measure the deacetylase activity of HDAC11. The compound is incubated with recombinant HDAC11 enzyme and a fluorogenic acetylated peptide substrate at various concentrations. HDAC activity is quantified by measuring the release of fluorophore. IC₅0 values are determined from dose-response curves. Selectivity profiling against other HDAC family members is performed to confirm specificity.
|
| Cell Assay |
For in vitro cellular experiments, FT895 is tested in cell lines expressing HDAC11. Cells are cultured in appropriate media and treated with various concentrations of the compound. HDAC11 activity is assessed by measuring acetylation levels of HDAC11 substrates using Western blotting. Cell viability, proliferation, and apoptosis are evaluated using standard assays. The compound's effects on HDAC11-dependent gene expression are analyzed by qPCR.
|
| Animal Protocol |
For in vivo animal experiments, FT895 can be administered to animals via various routes including oral gavage, intravenous injection, or intraperitoneal injection. The compound's efficacy can be evaluated in models of cancer, fungal infections, or viral infections. Typical dosing regimens may range from 1 to 50 mg/kg. Pharmacodynamic markers such as acetylation levels are measured in tissues. Disease progression and physiological parameters are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of FT895 are not extensively detailed in the public literature. As a small molecule with a molecular weight of 352.31, it may have reasonable oral bioavailability and tissue distribution. Detailed parameters such as Cₘₐₓ, Tₘₐₓ, AUC, half-life, and clearance would need to be determined through comprehensive PK studies. The compound's metabolism and excretion pathways remain to be fully characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for FT895 are limited, as it is primarily a research tool. As an HDAC11 inhibitor, its toxicity would depend on the importance of HDAC11 for normal cellular function. Comprehensive toxicology studies including acute and repeated-dose toxicity, genotoxicity, and cardiotoxicity assessments would be needed for further development. Appropriate safety precautions should be taken when handling this compound.
|
| References | |
| Additional Infomation |
FT895 is a research compound used to study HDAC11 biology. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a highly potent and exceptionally selective HDAC11 inhibitor with an IC₅0 of 3 nM.
|
| Molecular Formula |
C16H15F3N4O2
|
|---|---|
| Molecular Weight |
352.311113595963
|
| Exact Mass |
352.114
|
| CAS # |
2225728-57-2
|
| Related CAS # |
2225728-57-2
|
| PubChem CID |
134492522
|
| Appearance |
White to light yellow solid
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
514
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1(C2=CC=CC(=C2CN1C3=NC=C(N=C3)C(F)(F)F)C(=O)NO)C
|
| InChi Key |
XCLPBILTRRWOIL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H15F3N4O2/c1-15(2)11-5-3-4-9(14(24)22-25)10(11)8-23(15)13-7-20-12(6-21-13)16(17,18)19/h3-7,25H,8H2,1-2H3,(H,22,24)
|
| Chemical Name |
N-hydroxy-1,1-dimethyl-2-[5-(trifluoromethyl)pyrazin-2-yl]-3H-isoindole-4-carboxamide
|
| Synonyms |
FT895
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~125 mg/mL (~354.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8384 mL | 14.1920 mL | 28.3841 mL | |
| 5 mM | 0.5677 mL | 2.8384 mL | 5.6768 mL | |
| 10 mM | 0.2838 mL | 1.4192 mL | 2.8384 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
